Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- J. EikelboomS. Connolly S. Yusuf
- 27 August 2017
Medicine
Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
- J. SteffelP. Verhamme W. Shimizu
- 21 April 2018
Medicine
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
- H. HeidbuchelP. Verhamme Paulus Kirchhof
- 1 October 2015
Medicine
The current manuscript is an update of the original Practical Guide, published in June 2013, and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
- H. BüllerH. Décousus P. Wells
- 10 October 2013
Medicine
Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism.
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
- H. HeidbuchelP. Verhamme P. Kirchhof
- 1 May 2013
Medicine
New oral anticoagulant drugs are an alternative for vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation (AF) and many unresolved questions on how to optimally use these drugs in specific clinical situations remain.
Oral rivaroxaban for symptomatic venous thromboembolism.
- R. BauersachsS. Berkowitz S. Schellong
- 23 December 2010
Medicine
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- G. RaskobN. Es Hokusai Vte Cancer Investigators
- 1 July 2019
Medicine
Journal of Vascular Surgery: Venous and Lymphatic…
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
- T. OrtelI. Neumann Yuqing Zhang
- 2 October 2020
Medicine
Recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range, and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
- S. ConnollyM. Crowther T. Milling
- 7 February 2019
Medicine
In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduced anti–factor Xa activity, and 82% of patients had excellent or good hemostatic efficacy at 12 hours, as adjudicated according to prespecified criteria.
Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism
Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.
...
...